BMRN— BIOMARIN PHARMACEUTICAL INC

MaterialsBiotechnology$13.5B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$3.22B+12.9%	$2.85B+18.0%	$2.42B+15.4%	$2.10B
Cost of sales	$717.4M+23.6%	$580.2M+9.1%	$532.1M+5.8%	$503.0M
Research and development	$921.9M+23.4%	$747.2M+0.1%	$746.8M+15.0%	$649.6M
Selling, general and administrative	$1.15B+14.3%	$1.01B+13.1%	$892.4M+8.4%	$823.2M
Intangible asset amortization	$19.4M-55.2%	$43.3M-30.5%	$62.2M-7.4%	$67.2M
Gain on sale of nonfinancial assets	$0+100.0%	-$10.0M	$0+100.0%	-$108.0M
Total operating expenses	$2.81B+18.7%	$2.37B+6.1%	$2.23B+15.4%	$1.94B
INCOME FROM OPERATIONS	$409.5M-15.4%	$484.2M+160.6%	$185.8M+15.4%	$161.0M
Interest income	$74.9M+0.0%	$74.9M+28.4%	$58.3M+223.5%	$18.0M
Interest expense	-$10.9M+14.0%	-$12.7M+26.9%	-$17.3M-8.5%	-$16.0M
Other income (expense), net	$9.0M+292.7%	-$4.7M+87.8%	-$38.2M-183.9%	-$13.5M
INCOME BEFORE INCOME TAXES	$482.5M-10.9%	$541.8M+187.3%	$188.6M+26.1%	$149.6M
Provision for income taxes	$133.6M+16.3%	$114.9M+449.3%	$20.9M+161.0%	$8.0M
NET INCOME	$348.9M-18.3%	$426.9M+154.6%	$167.6M+18.4%	$141.6M
EARNINGS PER SHARE, BASIC (in dollars per share)	$1820.00-19.1%	$2250.00+152.8%	$890.00+17.1%	$760.00
EARNINGS PER SHARE, DILUTED (in dollars per share)	$1800.00-18.6%	$2210.00+154.0%	$870.00+16.0%	$750.00
Weighted-average common shares outstanding, basic (in shares)	191.8M+0.9%	190.0M+1.2%	187.8M+1.4%	185.3M
Weighted average common shares outstanding, diluted (in shares)	197.4M+0.3%	196.7M+2.7%	191.6M+1.4%	189.0M
Net product revenues
Royalty and other revenues

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.